Inner Quaternary Ammonium Salt (e.g., Betaine, Etc.) Patents (Class 514/556)
-
Publication number: 20130190398Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.Type: ApplicationFiled: March 15, 2013Publication date: July 25, 2013Applicant: ALLERGAN, INC.Inventor: Allergan, Inc.
-
Patent number: 8486916Abstract: It is intended to find novel pharmaceutical use of sphingomyelin and to provide preventive or therapeutic agents for various diseases as well as a food and drink product and feed comprising any of these agents. The present invention provides a pharmaceutical agent which contains sphingomyelin as an active ingredient and is any of the following agents: 1) a sialomucin secretion promoter, 2) an agent for preventing drunken sickness (hangover), 3) an antiallergic agent, 4) an antioxidant, 5) an agent for defending against infection, 6) a hair growth agent, 7) a therapeutic agent for demyelinating disease, 8) an anti-pigmentation agent, 9) an anti-inflammatory agent, and 10) an agent for improving learning ability. The present invention also provides a food and drink product or feed, characterized by comprising the agent. It is preferred that the sphingomyelin should be derived from milk.Type: GrantFiled: November 14, 2012Date of Patent: July 16, 2013Assignee: Megmilk Snow Brand Co., Ltd.Inventors: Ken Kato, Susumu Miura, Leo Tanaka, Hiroshi Ueno, Noriko Ueda, Yuko Haruta, Toshimitsu Yoshioka
-
Publication number: 20130172414Abstract: A pharmaceutical composition comprising levocarnitine and dobesilate is provided. Also provided are a method for regulating the level of serum creatinine and/or blood urea nitrogen and a method for treating and/or preventing the diseases influencing renal function, for example, including but not limiting to various primary, secondary nephritis, renal lesions, renal insufficiency, nephritic syndrome, even renal failure, uremia, as well as the complications induced by the diseases and/or disorders influencing renal function for example, such as cardiovascular diseases, diabetes and the like.Type: ApplicationFiled: June 10, 2011Publication date: July 4, 2013Applicants: TIANJIN NANKAI SHARE PHARMACEUTICAL SCIENCE & TECHNOLOGY CO., LTD., XIZANG LINZHI PARKSON PHARMACEUTICAL CO., LTD., NANKAI SHARE PHARMACEUTICAL CO., LTD., LIAONING SEBEST PHARMACEUTICL CO., LTD.Inventors: Yong Wang, Xin Zhao, Mo Chen, Ning Tian
-
Publication number: 20130156855Abstract: One example embodiment includes a chemical composition for the treatment of acne. The chemical composition includes pantothenic acid and L-Carnitine.Type: ApplicationFiled: December 16, 2011Publication date: June 20, 2013Inventor: Aviv Ben-Menachem
-
Publication number: 20130137651Abstract: The present invention relates to a solid powder composed of a mixture of a natural or a synthetic polymer which forms a gel, a buffer, such as an hydroxyacid or a dicarboxyacid, a saccharide, one or more drugs useful for the treatment of diseases of the eyes and optionally one or more excipients and/or regulators of the osmotic pressure ophthalmologically acceptable.Type: ApplicationFiled: January 25, 2013Publication date: May 30, 2013Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventor: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.
-
Publication number: 20130096195Abstract: The invention describes the use of betaine alone for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.Type: ApplicationFiled: December 10, 2012Publication date: April 18, 2013Inventor: Jallal Messadek
-
Publication number: 20130096143Abstract: The invention relates to small molecules having biological and therapeutic activity. Particularly, the invention relates to small molecules having lipolytic and anti-adipogenic activity. Two examples of such molecules are 4-methyl-2-(octanoylamino) pentanoic acid and N-isopentyloctanamide. The invention further relates to methods of preventing or treating skin conditions such as cellulite using small molecules having lipolytic and anti-adipogenic activity.Type: ApplicationFiled: June 28, 2011Publication date: April 18, 2013Applicant: HELIX BIOMEDIX, INC.Inventors: Timothy J. Falla, Lijuan Zhang
-
Patent number: 8410156Abstract: Compositions comprising ergothioneine and a trimethylamine absorber are provided. Also provided are methods for preventing, reducing or minimizing the fishy, amine odor, due to trimethylamine, that is associated with the processing and/or storage of a preparation containing ergothioneine, by combining with the ergothioneine, during processing or prior to storage, a trimethylamine absorber in an amount sufficient to prevent the detection of any trimethylamine odor by the human nose. A method is further provided for ameliorating the methylamine odor associated with an aqueous ergothioneine-containing preparation after it has developed a fishy trimethylamine odor.Type: GrantFiled: January 30, 2009Date of Patent: April 2, 2013Assignee: ELC Management, LLCInventor: Daniel B. Yarosh
-
Patent number: 8409550Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to about 50% of at combination of retinoid boosters.Type: GrantFiled: June 21, 2012Date of Patent: April 2, 2013Assignee: Unilever Home & Personal Care, USA, Division of Conopco, Inc.Inventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20130079407Abstract: An aqueous composition adapted to kill bacteria in both planktonic and biofilm states is lethal toward a wide spectrum of gram positive and gram negative bacteria as well as other microbes. The composition, which is slightly to moderately acidic, includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. The composition can be applied directly to a site of bacterial growth. Even when the bacteria is in biofilm form, the surfactant component(s) begin to kill the bacteria before the macro-molecular matrix is removed or dislodged from the site.Type: ApplicationFiled: November 16, 2012Publication date: March 28, 2013Applicant: Microbial Defense Systems, LLCInventor: Microbial Defense Systems, LLC
-
Patent number: 8394854Abstract: The use of L-carnitine, or one of its pharmaceutically acceptable salts, is described in combination with glucose for the preparation of a medicament useful for diminishing the number of deaths caused by acute myocardial infarction, for reducing the number of days infarction patients spend in intensive care in hospital, and for reducing the number of episodes of post-infarction heart failure, in which the L-carnitine is administered intravenously within only a few hours of the onset of symptoms of acute myocardial infarction at an initial dose of 9 grams a day in combination with 1000-1500 mL of a 5% glucose solution for 5 days, after which the L-carnitine treatment is continued at a dose of 4 grams a day administered orally.Type: GrantFiled: December 20, 2010Date of Patent: March 12, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Aleardo Koverech
-
Patent number: 8389574Abstract: The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance.Type: GrantFiled: March 21, 2008Date of Patent: March 5, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Claudio Cavazza, Paolo Carminati
-
Publication number: 20130041028Abstract: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).Type: ApplicationFiled: February 25, 2011Publication date: February 14, 2013Applicants: NORTHWESTERN UNIVERSITY, CATALYST PHARMACEUTICAL PARTNERS, INC., BROOKHAVEN SCIENCE ASSOCIATESInventors: Richard B. Silverman, Stephen L. Dewey, Steven Miller
-
Publication number: 20130018014Abstract: The subject application relates to novel compositions containing a diffusion enhancing compound and their use in treating a variety of disorders.Type: ApplicationFiled: June 22, 2012Publication date: January 17, 2013Applicant: Diffusion Pharmaceuticals LLCInventor: John L. Gainer
-
Publication number: 20130011498Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: January 10, 2013Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Patent number: 8349893Abstract: This invention relates to novel 4-trimethylammoniobutyrates of the formula wherein A1, R1, m and n are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds inhibit carnitine palmitoyl transferase (CPT) activity, in particular CPT2 activity, and can be used as medicaments.Type: GrantFiled: April 28, 2009Date of Patent: January 8, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Mirjana Andjelkovic, Simona M. Ceccarelli, Odile Chomienne, Patrizio Mattei
-
Publication number: 20130005806Abstract: Embodiments of the invention include determining whether an individual has autism spectrum disorder or is at risk for developing autism spectrum disorder or at risk for regression of or into autism spectrum disorder. Specific embodiments include the determination of indicative levels of carnitine or other metabolites in carnitine biosynthesis and may include assaying for mutations in TMLHE, including in exon 2, for example. In some cases one can assay for mutations in TMLHE in the absence of biochemical analysis of carnitine biosynthesis metabolites. An individual with deficiency in TMLHE and/or carnitine levels may be administered carnitine, acetylcarnitine, butyrobetaine, or a combination thereof, for example.Type: ApplicationFiled: June 18, 2012Publication date: January 3, 2013Inventors: Arthur L. Beaudet, Frederic M. Vaz
-
Publication number: 20130005810Abstract: The present invention relates to a method for controlling the growth of bacterial biomass in an aqueous system, including adding to the aqueous system or contacting the aqueous system, with an efficient amount of an uncoupling agent selected from vanillin, pentaerythritol and a betaine of general formula (1): (R)3N+?[CH2]n?CO2? wherein the R groups, are identical or different, and are selected from a linear or branched alkyl group having 1 to 8 carbon atoms, and n is a number between 1 and 5.Type: ApplicationFiled: July 26, 2010Publication date: January 3, 2013Applicant: RHODIA OPERATIONSInventors: Roland Jacquot, Luc Louvel, Philippe Marchal, Philippe Marion, Gilles Moreau, Agnes Pilas-Begue
-
Publication number: 20120329872Abstract: A new finished feed for domestic pets is proposed, containing at least one guanidinoacetic acid component as the active component with regard to nutritional physiology. The new finished feed which preferably has a water content of >8% by weight, can be produced in an extremely economical manner, wherein the main component has a significantly higher stability during passage through the gastrointestinal tract and is therefore only converted into creative under physiological conditions. For this reason the guanidinoacetic acid is also utilized to a high degree by the target group which is in particular cats and dogs.Type: ApplicationFiled: July 2, 2012Publication date: December 27, 2012Applicant: Alzchem Trostberg GmbHInventors: Thomas Gastner, Hans-Peter Krimmer
-
Publication number: 20120315326Abstract: Enteric coated multiparticulate compositions that use a L-carnitine compound an active ingredient are disclosed. The multiparticulates have spheroidal core comprising a L-carnitine, microcrystalline cellulose, and hydroxypropyl methylcellulose; a sub-coat comprising hydroxypropyl methyl cellulose on the spheroidal core; and an enteric coat on the sub-coated spheroidal core. The average diameter of the particulates is about 0.1-3 mm. Other aspects of the invention include methods of making and methods of using the multiparticulate compositions.Type: ApplicationFiled: June 6, 2012Publication date: December 13, 2012Inventors: Syed SHAH, Noreen HASSAN
-
Patent number: 8318805Abstract: The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both immunological and functional (activity) expression of Tissue Factor Pathway Inhibitor (TFPI) in a mammal, particularly a human.Type: GrantFiled: May 10, 2007Date of Patent: November 27, 2012Inventor: Jallal Messadek
-
Publication number: 20120277176Abstract: In accordance with certain embodiments of the present disclosure, a self-assembling biodegradable nanoparticle is provided. The nanoparticle includes Cys-Val-Val-Val-Val-Val-Val-Lys-Lys conjugated with a synthetic polymer and has a diameter of from about 50 nm to about 150 nm.Type: ApplicationFiled: October 25, 2010Publication date: November 1, 2012Inventors: Paul R. Thompson, Corey P. Causey
-
Publication number: 20120263698Abstract: A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described.Type: ApplicationFiled: April 20, 2012Publication date: October 18, 2012Inventor: Elizabeth K. Barber
-
Publication number: 20120258061Abstract: A skin care product comprising from about 0.001% to about 10% of a retinoid in combination with 0.0001% to about 50% of at combination of retinoid hoosters.Type: ApplicationFiled: June 21, 2012Publication date: October 11, 2012Applicant: CONOPCO, INC., D/B/A UNILEVERInventors: Stewart Paton Granger, Ian Richard Scott, Robert Mark Donovan, Susanne Teklits Iobst, Lisa Licameli
-
Publication number: 20120253238Abstract: Solubilizing compositions are provided. The compositions comprise at least one zwitterionic surfactant and at least one nonionic surfactant. In one embodiment, the compositions may be useful for solubilizing and remodeling and/or removing tissue on or beneath a patient's skin, optionally in conjunction with the application of energy to a region of interest on the skin. In one embodiment, at least one analyte may be collected and analyzed from the solubilized tissue.Type: ApplicationFiled: May 16, 2012Publication date: October 4, 2012Inventors: Samir Mitragotri, Russell M. Lebovitz, Beyeong Hee Hwang
-
Publication number: 20120220656Abstract: New compound 4-[ethyl(dimethyl)ammonio]butanoate, method of preparation thereof and use in the treatment of cardiovascular disease.Type: ApplicationFiled: October 22, 2010Publication date: August 30, 2012Applicant: JSC GRINDEKSInventors: Ivars Kalvins, Maija Dambrova, Edgars Liepins, Osvalds Pugovics, Reinis Vilskersts, Janis Kuka, Solveiga Grinberga, Einars Loza
-
Publication number: 20120220643Abstract: A method for increasing the vasodilative characteristics of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20120220642Abstract: Methods for increasing the bioabsorption of amino acids and for preventing the development of nitrate tolerances in a human or animal are disclosed. The methods include administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Aspartic Acid, Cysteine, Glycine, Lysine, Methionine, Proline, Tyrosine, Phenylalanine, Carnitine, Taurine, and Betaine.Type: ApplicationFiled: May 7, 2012Publication date: August 30, 2012Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Publication number: 20120214870Abstract: Methods for the diagnosis and treatment of chronic fatigue syndrome (CFS) are disclosed based upon the finding that particular individual acylcarnitines are present in modified concentrations (ie decreased or increased concentrations) in CFS patients compared to healthy control subjects. In one form of the invention, a diagnostic method comprises determining a concentration of at least one individual acylcarnitine compound (eg oleyl-L-carnitine and linoleyl-L-carnitine) in a body sample from a test subject and comparing the concentration to a reference concentration, wherein a difference in the concentration of the at least one individual acylcarnitine from the test subject compared to the reference concentration is indicative of CFS.Type: ApplicationFiled: August 30, 2010Publication date: August 23, 2012Applicant: UNIVERSITY OF SOUTH AUSTRALIAInventors: Allan Mark Evans, Stephanie Elizabeth Reuter, Peter Lance Wigley
-
Publication number: 20120189714Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189716Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji
-
Publication number: 20120189717Abstract: The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 ?-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.Type: ApplicationFiled: January 11, 2012Publication date: July 26, 2012Applicant: ABBOTT LABORATORIESInventors: Jeffrey H. Baxter, Anne C. Voss, Pradip Mukerji, Michael J. Tisdale
-
Publication number: 20120172435Abstract: The current invention provides methods and compositions for treating sensorineural hearing loss including but not limited to acute acoustic trauma (AAT). The composition 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC). Preferably, the compositions for treating AAT will be administered orally. However, other methods which deliver the compositions for treating AAT systemically to the body should work equally well.Type: ApplicationFiled: August 24, 2010Publication date: July 5, 2012Inventors: Richard Dana Kopke, Robert A. Floyd
-
Publication number: 20120172324Abstract: The present disclosure relates generally to a co-formulation or co-administration of acetaminophen with one or more chemicals that are metabolites or their derivatives in the methionine and glutathione biosynthesis pathways, for protection against acetaminophen-induced liver toxicity. The formulation may comprise acetaminophen and diet supplements such as S-methylmethionine (SMM). The present disclosure also encompasses methods of providing pain or fever relief with protection against acetaminophen-induced liver injury with the formulations described herein. Embodiments of the present disclosure also include co-formulation or co-administration of an agent and one or more other chemicals for reducing agent-induced liver toxicity via depletion of glutathione.Type: ApplicationFiled: September 16, 2010Publication date: July 5, 2012Inventors: Hong-Hsing Liu, Gary Allen Peltz, Guochun Liao, Timothy Alan Garrow
-
Publication number: 20120172436Abstract: The present invention relates to betaine or a composition comprising the same for accelerating liver regeneration, more particularly, a therapeutic pharmaceutical composition comprising betaine represented by formula 1 as an active ingredient for promoting the recovery of injured or resected liver to the normal liver. The most effective treatment for chronic liver disease, particularly in the terminal stage, is hepatectomy and liver transplantation. In Living Donor Liver Transplantation (LDLT) that has been increasing since 1990, rapid regeneration of liver tissues is essential for both donor and recipient to inhibit complications and thus for the success of the treatment. Betaine accelerates the recovery and growth of injured liver to the normal liver, so that it can be effectively used for the successful LDLT or therapeutic hepatectomy.Type: ApplicationFiled: August 24, 2010Publication date: July 5, 2012Applicant: SNU R&DB FOUNDATIONInventor: Young Chul Kim
-
Publication number: 20120157392Abstract: Method of treating a patient suffering from apoptosis of tissue by administering to the patient a therapeutically effective amount of one or more ketogenic compounds such that a physiological ketosis is produced which arrests the apoptosis.Type: ApplicationFiled: December 20, 2011Publication date: June 21, 2012Applicant: BTG INTERNATIONAL LIMITEDInventors: KEITH FRANK MARTIN, DAVID JOHN HEAL, ELIZABETH JAGGER
-
Publication number: 20120148685Abstract: The present invention relates to compositions comprising (i) an activator of transport of fatty acids into the mitochondria; (ii) an activator of fatty acid oxidation; and (iii) an inhibitor of fatty acid biosynthesis, and methods for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome, dyslipidemias, obesity, and/or cardiovascular disorders in a subject.Type: ApplicationFiled: June 10, 2010Publication date: June 14, 2012Applicant: Engergy4Life AGInventor: Markus Rohner
-
Publication number: 20120128724Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: ApplicationFiled: November 22, 2011Publication date: May 24, 2012Applicant: The Regents of the University of Colorado, a body corporateInventors: M. Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Publication number: 20120108632Abstract: The invention concerns in one embodiment a method of treating glaucoma or elevated intraocular pressure comprising administering a pharmaceutically effective amount of a composition comprising at least one prenyltransferase inhibitor. In another embodiment, the invention concerns a composition for the treatment of elevated intraocular pressure and glaucoma comprising a pharmaceutically effective amount of a prenyltransferase inhibitor.Type: ApplicationFiled: January 5, 2012Publication date: May 3, 2012Applicant: ALCON RESEARCH, LTD.Inventors: Allan R. Shepard, Debra L. Fleenor
-
Publication number: 20120101160Abstract: The present invention provides methods for treating glaucoma by administering compounds capable of stabilizing misprocessed or misfolded proteins that are responsible for the condition.Type: ApplicationFiled: December 14, 2005Publication date: April 26, 2012Inventors: Allan Shepard, Nasreen Jacobson, Abbot F. Clark
-
Publication number: 20120093809Abstract: The present invention relates to the use of an alkanoyl L-carnitine selected from the group consisting of acetyl, propionyl, valeryl, isovaleryl and butirryl L-carnitine; in combination with one or more chemotherapeutic agent selected from the group consisting of: a camptothecin derivative; an alkylating agent; an anti-neoplastic anti-metabolite; a platin compound; a topoisomerase inhibitor; a VEGF inhibitor; a tyrosine kinase inhibitor; an EGFR kinase inhibitor; an mTOR kinase inhibitor; an insulin-like growth factor I inhibitor; a Raf kinase inhibitor; a monoclonal antibody; a proteasome inhibitor; a HDAC inhibitor; toxins; and imides; for the treatment of neoplasms.Type: ApplicationFiled: December 1, 2009Publication date: April 19, 2012Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Claudio Cavazza, Giulia Tagliafico, Paolo Carminati, Gabriella Singrossi, Silvia Carminati, Giuseppe Paolo Carminati, Claudio Pisano
-
Publication number: 20120089105Abstract: The present invention relates to a skin patch comprising a matrix adhering to the skin and containing at least one active cosmetic substance and a combination with a skin wrapping to generate an effective compression for the treatment of cellulite and/or striae.Type: ApplicationFiled: December 16, 2011Publication date: April 12, 2012Applicant: BEIERSDORF AGInventors: Soeren JASPERS, Carsten HARTKOPF, Christian GAEDE, Stefan BODENSCHATZ, Katharina POST, Jens SCHULZ, Karl-Heinz WOELLER
-
Patent number: 8138372Abstract: The present invention covers zwitterionic, non-surface-active compounds in the form of carboxymethylated, short-chain dialkylaminoalkylamides and use thereof as therapeutic agent.Type: GrantFiled: June 12, 2008Date of Patent: March 20, 2012Assignee: Evonik Goldschmidt GmbHInventors: Sascha Herrwerth, Hans Henning Wenk, Burghard Gruning, Petra Allef, Uwe Begoihn
-
Publication number: 20120027879Abstract: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.Type: ApplicationFiled: August 3, 2011Publication date: February 2, 2012Inventor: Harry A. DUGGER, III
-
Publication number: 20120027723Abstract: The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Inventor: Serge Picaud
-
Patent number: 8097265Abstract: The invention relates to an aqueous foam disinfectant comprised of a special surfactant system, which consists of non-ionic and amphoteric surfactants, and of a synergistic disinfectant constituent, which consists of an antimicrobial agent having amino groups and of at least one additional antimicrobial agent.Type: GrantFiled: June 20, 2003Date of Patent: January 17, 2012Assignee: Ecolab USA Inc.Inventors: Holger Biering, Michael Decker
-
Publication number: 20120004592Abstract: Tissue solubilizing compositions are provided. The compositions comprise 3-(decyl dimethyl ammonio) propane sulfonate and polyethylene glycol dodecyl ether, such as tetraethylene glycol dodecyl ether. The compositions may be useful to solubilize tissue, including skin, mucosal membrane, and other tissue. The compositions may be further useful to preserve and recover analytes contained within the solubilized skin, mucosal membrane, and other tissue.Type: ApplicationFiled: April 27, 2011Publication date: January 5, 2012Applicant: The Regents of the University of CaliforniaInventors: Samir Mitragotri, Sumit Pallwal, Makoto Ogura, Russell M. Lebovitz
-
Publication number: 20120003158Abstract: The present invention provides various biomarkers of inflammatory bowel disease, including biomarkers for Crohn's disease and biomarkers for Ulcerative colitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods for distinguishing between inflammatory bowel diseases, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, methods of assessing efficacy of compositions for treating inflammatory bowel disease, methods of screening compositions for activity in modulating biomarkers of inflammatory bowel disease, methods of treating inflammatory bowel disease, as well as other methods based on biomarkers of inflammatory bowel disease.Type: ApplicationFiled: April 8, 2011Publication date: January 5, 2012Inventors: Danny ALEXANDER, Jeffrey SHUSTER, Joshua KORZENIK, Garrett ZELLA
-
Publication number: 20110313011Abstract: A method for increasing the bioabsorption of amino acids in a human or animal is disclosed. The method includes administering to the human or animal a pharmaceutically effective amount of an amino acid compound consisting essentially of a nitrate or nitrite of an amino acid selected from the group consisting of Arginine, Agmatine, Beta Alanine, Citrulline, Creatine, Glutamine, L-Histidine, Isoleucine, Leucine, Norvaline, Ornithine, and Valine.Type: ApplicationFiled: November 15, 2010Publication date: December 22, 2011Applicant: THERMOLIFE INTERNATIONAL, LLCInventors: Ronald Kramer, Alexander Nikolaidis
-
Patent number: 8076373Abstract: The present invention provides a method for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof. The method comprises contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is selected from the group consisting of pyruvates, pyruvate precursors, ?-keto acids having four or more carbon atoms, precursors of ?-keto acids having four or more carbon atoms, and the salts thereof, wherein mediation of reactive oxygen species results in mediation of peroxynitrous acid. The present invention further provides a pharmaceutical composition for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof.Type: GrantFiled: February 11, 2005Date of Patent: December 13, 2011Assignee: North Cell PharmaceticalInventor: Alain Martin